Sunitinib-induced microangiopathic hemolytic anemia with fatal outcome

Tony N. Talebi, Alexandra Stefanovic, Jaime R Merchan, Eric Lian, Orlando Silva

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Sunitinib, a new vascular endothelial growth factor receptor inhibitor, has demonstrated activity in renal cell carcinoma and is now widely used in the palliative treatment of patients with metastatic renal cell carcinoma. It is generally well tolerated but has been associated with a low incidence of grade 3 and 4 toxicities including fatigue, diarrhea, anorexia, mucositis, skin toxicity, immune thrombocytopenic purpura, hypertension, hypothyroidism, cytopenias, and decreased cardiac ejection fraction. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) is a rare condition that is severe and may be fatal. Several medications have been implicated in causing TTP-HUS including clopidogrel, mitomycin C, cisplatin. In this report, we describe a case of atypical HUS-microangiopathic hemolytic anemia during treatment with sunitinib in a patient with metastatic renal cell carcinoma. To our knowledge, this is the fourth case of microangiopathic hemolytic anemia associated with sunitinib described in the literature and the first case with fatal outcome despite treatment with plasmapheresis, dialysis, and withdrawal of sunitinib.

Original languageEnglish
JournalAmerican Journal of Therapeutics
Volume19
Issue number4
DOIs
StatePublished - Jul 1 2012

    Fingerprint

Keywords

  • microangiopathic hemolytic anemia
  • renal failure
  • sunitinib
  • Sutent
  • thrombocytopenia

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this